On Nov. 18, 2022, Pfizer and BioNTech announced results from an analysis examining the immune response induced by…
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
On Nov. 16, 2022, the Cancer Prevention and Research Institute of Texas (CPRIT) approved $12 million in recruitment…
On Nov. 14, 2022, Moderna announced that both of Moderna’s bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger…
On Nov. 10, 2022, Pfizer and BioNTech announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
On Nov. 9, 2022, researchers at the University of Missouri announced they had identified the highly prevalent, specific…
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
On Nov. 8, 2022, Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS…
On Nov. 4, 2022, Moderna announced that Health Canada had authorized the use of its BA.4/BA.5 Omicron-targeting bivalent…
On Nov. 4, 2022, Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a…
On Nov. 1, 2022, Pfizer announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal…
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
On Oct. 27, 2022, Inovio Pharma announced that it has discontinued its internally funded efforts to develop INO-4800…
On Oct. 25, 2022, Pacific Northwest National Laboratory (PNNL) announced that scientists have shown that they can detect…
On Oct. 20, 2022, the National Institutes of Health announced that a three-dose course of the hepatitis B…
On Oct. 19, 2022, Moderna announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after…
On Oct. 19, 2022, Pfizer and BioNTech announced that the European Medicines Agencyï¾’s (EMA) Committee for Medicinal Products…
On Oct. 17, 2022, Moderna and Gavi, the Vaccine Alliance, have mutually agreed to cancel remaining pending orders…
On Oct. 13, 2022, Pfizer and BioNTech announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating…
On Oct. 13, 2022, researchers from the University of Oxford reported findings from a study exploring how certain…
On Oct. 11, 2022, researchers from the University of Oxford have reported new findings from a Phase 1…
On Oct. 10, 2022, Novavax announced that partner, SK bioscience, had submitted a Post Approval Change Application to…
On Oct. 10, 2022, Novavax announced that Switzerlands Federal Office of Public Health had recommended Nuvaxovidï¾™(NVX-CoV2373) as a…
On Oct. 7, 2022, the U.S. Food and Drug Administration approved Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and…
On Oct. 7, 2022, Pfizer and BioNTech announced that Health Canada has authorized COMIRNATY Original & Omicron BA.4/BA.5…
On Oct. 6, 2022, researchers in Japan released a study that described the development and application of the…
On Oct. 4, 2022, Washington University in St. Louis announced it had licensed the rights to develop, manufacture…
On Sept. 28, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
On Sept. 28, 2022, Moderna announced that the European Medicines Agency had accepted a variation for the evaluation…
On Sept. 27, 2022, the National Institutes of Health announced that a large international study had confirmed the…